{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:02Z","timestamp":1792112282212,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T00:00:00Z","timestamp":1431043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T00:00:00Z","timestamp":1431043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10637-015-0247-1","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:16:57Z","timestamp":1430957817000},"page":"901-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors"],"prefix":"10.1007","volume":"33","author":[{"given":"Mark J.","family":"Ratain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir D.","family":"Undevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Miguel-Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,8]]},"reference":[{"key":"247_CR1","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1021\/jo960877+","volume":"61","author":"MT Hamann","year":"1996","unstructured":"Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet bryopsis sp. (1). J Org Chem 61:6594\u20136600","journal-title":"J Org Chem"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00001813-200108000-00003","volume":"12","author":"RW Sparidans","year":"2001","unstructured":"Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, Schellens JH, Beijnen JH (2001) Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer Drugs 12:575\u2013582","journal-title":"Anticancer Drugs"},{"key":"247_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-3-540-30880-5_16","volume":"43","author":"G Faircloth","year":"2006","unstructured":"Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363\u2013379","journal-title":"Prog Mol Subcell Biol"},{"key":"247_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3816\/CLC.2009.n.041","volume":"10","author":"M Provencio","year":"2009","unstructured":"Provencio M, Sanchez A, Gasent J, Gomez P, Rosell R (2009) Cancer treatments: can we find treasures at the bottom of the sea? Clin Lung Cancer 10:295\u2013300","journal-title":"Clin Lung Cancer"},{"key":"247_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejphar.2011.05.064","volume":"667","author":"T Varadi","year":"2011","unstructured":"Varadi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szollosi J, Nagy P (2011) ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 667:91\u201399","journal-title":"Eur J Pharmacol"},{"key":"247_CR6","doi-asserted-by":"publisher","first-page":"e19042","DOI":"10.1371\/journal.pone.0019042","volume":"6","author":"JM Molina-Guijarro","year":"2011","unstructured":"Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, David M, Nunez L, Martinez-Leal JF, Moneo V, Cuevas C, Lillo MP, Villalobos Jorge C, Valenzuela C, Galmarini CM (2011) Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS ONE 6:e19042","journal-title":"PLoS ONE"},{"key":"247_CR7","doi-asserted-by":"publisher","first-page":"9779","DOI":"10.1158\/0008-5472.CAN-08-1981","volume":"68","author":"AB Herrero","year":"2008","unstructured":"Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, Moreno S (2008) Levels of SCS7\/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68:9779\u20139787","journal-title":"Cancer Res"},{"key":"247_CR8","unstructured":"Molina-Guijarro JM, Moneo V, Mart\u00ednez-Leal JF, Cuevas C, Garc\u00eda-Fern\u00e1ndez LF, Galmarini CM (2009) PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. p. Abstract #888"},{"key":"247_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1358\/dof.2010.035.04.1497635","volume":"35","author":"C Coronado","year":"2010","unstructured":"Coronado C, Galmarini CM, Alfaro V, Yovine A (2010) Elisidepsin. Drugs Future 35:287\u2013296","journal-title":"Drugs Future"},{"key":"247_CR10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ejca.2009.03.003","volume":"45","author":"YH Ling","year":"2009","unstructured":"Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y (2009) Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 45:1855\u20131864","journal-title":"Eur J Cancer"},{"key":"247_CR11","unstructured":"Elices M, Lepage DJ, Grant W, Alvarez E, Guillen MJ, Cuevas C, Aviles P, Faircloth G (2006) Activity of PM02734 against human breast and prostate tumors. Proc Am Assoc Cancer Res 47:Abst. 4712"},{"key":"247_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/md11030944","volume":"11","author":"M Serova","year":"2013","unstructured":"Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E (2013) Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound. Mar Drugs 11:944\u2013959","journal-title":"Mar Drugs"},{"key":"247_CR13","first-page":"317","volume":"41","author":"C Teixido","year":"2012","unstructured":"Teixido C, Arguelaguet E, Pons B, Aracil M, Jimeno J, Somoza R, Mares R, Ramon YCS, Hernandez-Losa J (2012) ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. Int J Oncol 41:317\u2013324","journal-title":"Int J Oncol"},{"key":"247_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138\u20131147","journal-title":"J Natl Cancer Inst"},{"key":"247_CR15","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events (CTCAE) v.3.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf:1-72"},{"key":"247_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"247_CR17","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/rcm.2644","volume":"20","author":"J Yin","year":"2006","unstructured":"Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth G (2006) Development of a liquid chromatography\/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom 20:2735\u20132740","journal-title":"Rapid Commun Mass Spectrom"},{"key":"247_CR18","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user's guides (1989\u20132009). Icon Development Solutions"},{"key":"247_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-012-1951-6","volume":"70","author":"R Salazar","year":"2012","unstructured":"Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR (2012) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70:673\u2013681","journal-title":"Cancer Chemother Pharmacol"},{"key":"247_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11:371\u2013380","journal-title":"AAPS J"},{"key":"247_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"247_CR22","doi-asserted-by":"crossref","unstructured":"Evans TR, Oaknin A, Jones RJ, Vandermeeren A, Coronado C, Soto-Matos A, Germa JR, Crawford D, Frontelo P, Salazar R (2009) Phase I dose-escalating study of PM02734 in a 24-h infusion schedule every 21 days in advanced solid tumors. ASCO American Society of Clinical Oncology, 45th Annual Meeting, May 29- Jun 2, 2009. Orlando, FL. J Clin Oncol 27(15 Supl):110, Abstrac no. 2511","DOI":"10.1200\/jco.2009.27.15_suppl.2511"},{"key":"247_CR23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/annonc\/mdq422","volume":"21","author":"C Coronado","year":"2010","unstructured":"Coronado C, Kahatt C, Szyldergemajn S, Iglesias JL, Florez A, Yovine A (2010) Transient isolated transaminase increases do not correlate with permanent clinical liver damage: phase I experience with elisidepsin. Ann Oncol 21:180\u201318, abstract No. 553","journal-title":"Ann Oncol"},{"key":"247_CR24","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1078-0432.CCR-04-1534","volume":"11","author":"JM Rademaker-Lakhai","year":"2005","unstructured":"Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH (2005) Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 11:1854\u20131862","journal-title":"Clin Cancer Res"},{"key":"247_CR25","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/1078-0432.CCR-07-4366","volume":"14","author":"B Pardo","year":"2008","unstructured":"Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, Garcia M, Salazar R, Lopez A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM (2008) Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-h infusion to patients with advanced solid tumors. Clin Cancer Res 14:1116\u20131123","journal-title":"Clin Cancer Res"},{"key":"247_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ejca.2008.12.005","volume":"45","author":"S Martin-Algarra","year":"2009","unstructured":"Martin-Algarra S, Espinosa E, Rubio J, Lopez Lopez JJ, Manzano JL, Carrion LA, Plazaola A, Tanovic A, Paz-Ares L (2009) Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer 45:732\u2013735","journal-title":"Eur J Cancer"},{"key":"247_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10637-013-0060-7","volume":"32","author":"F Goldwasser","year":"2014","unstructured":"Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernandez-Garcia EM, Kahatt CM, Paramio PG, Dios JL, Miguel-Lillo B, Raymond E (2014) Phase I study of elisidepsin (Irvalec(R)) in combination with carboplatin or gemcitabine in patients with advanced malignancies. Investig New Drugs 32:500\u2013509","journal-title":"Investig New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0247-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0247-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:43:53Z","timestamp":1678509833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0247-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0247-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,8]]},"assertion":[{"value":"13 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}